본문 바로가기
KERD
논문KCI 등재

Factors influencing occurrence of metachronous gastric cancer after endoscopic resection: a systematic review and meta-analysis

김병욱|박재명|Joon Sung Kim|Yu Kyung Cho|Myung-Gyu Choi|Younghee Choe
대한내과학회 (The Korean Association Of Internal Medicine)|2023.11|The Korean Journal of Internal Medicine|제38권 제6호|pp. 831-843

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Meta-analysisStomach neoplasmsSecond primary neoplasmsMetaplasiaAtrophic gastritis
주제분류내과학

초록

Background/Aims: Metachronous gastric cancer (MGC) can occur after endoscopic resection for gastric cancer. Further studies on factors other than Helicobacter pylori infection are needed. This systematic review and meta-analysis aimed to evaluate risk factors for metachronous recurrence of endoscopically resected gastric cancer. Methods: We searched medical literature published by February 2023 and identified patients with MGC after endoscopic resection for gastric cancer. The occurrence of MGC and the presence of intestinal metaplasia (IM), severe atrophic gastritis (AG), and H. pylori infection were quantitatively analyzed. Results: We identified 2,755 patients from nine cohort studies who underwent endoscopic resection for gastric cancer by 2018. Those with severe AG or presence of IM had a significantly higher incidence of MGC than those without (RR 2.00, 95% CI 1.35–2.98, I2 = 52% for severe atrophy on antrum; RR 7.08, 95% CI 3.63–13.80, I2 = 0% for antral IM). Absolute risk difference of MGC occurrence was 7.1% in those with severe AG and 9.2% in those with IM. The difference in incidence rate per 1,000 person-years was 17.5 person-years for those with severe AG and 24.7 person-years for those with IM. However, H. pylori eradication did not significantly affect the occurrence of MGC (RR 1.18, 95% CI 0.88–1.59, I2 = 10%). Conclusions: Gastric cancer patients with severe AG or presence of IM had a 2.0-fold or 7.0-fold higher risk of MGC occurrence after endoscopic resection than those without, respectively. They need more stringent follow-up to monitor MGC occurrences (CRD42023410940).

Abstract

Background/Aims: Metachronous gastric cancer (MGC) can occur after endoscopic resection for gastric cancer. Further studies on factors other than Helicobacter pylori infection are needed. This systematic review and meta-analysis aimed to evaluate risk factors for metachronous recurrence of endoscopically resected gastric cancer. Methods: We searched medical literature published by February 2023 and identified patients with MGC after endoscopic resection for gastric cancer. The occurrence of MGC and the presence of intestinal metaplasia (IM), severe atrophic gastritis (AG), and H. pylori infection were quantitatively analyzed. Results: We identified 2,755 patients from nine cohort studies who underwent endoscopic resection for gastric cancer by 2018. Those with severe AG or presence of IM had a significantly higher incidence of MGC than those without (RR 2.00, 95% CI 1.35–2.98, I2 = 52% for severe atrophy on antrum; RR 7.08, 95% CI 3.63–13.80, I2 = 0% for antral IM). Absolute risk difference of MGC occurrence was 7.1% in those with severe AG and 9.2% in those with IM. The difference in incidence rate per 1,000 person-years was 17.5 person-years for those with severe AG and 24.7 person-years for those with IM. However, H. pylori eradication did not significantly affect the occurrence of MGC (RR 1.18, 95% CI 0.88–1.59, I2 = 10%). Conclusions: Gastric cancer patients with severe AG or presence of IM had a 2.0-fold or 7.0-fold higher risk of MGC occurrence after endoscopic resection than those without, respectively. They need more stringent follow-up to monitor MGC occurrences (CRD42023410940).

참고문헌 (39)

  1. Lee SH, "Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea", Int J Rheum Dis, 23, pp.342~349 (2020)
  2. Najmeh S, "Comparing laparoscopic to endoscopic resections for early gastric cancer in a high volume North American Center", J Gastrointest Surg, 20, pp.1547~1553 (2016)
  3. Liu Q, "Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer : a systematic review and meta-analysis", Int J Surg, 73, pp.28~41 (2020)
  4. Abdelfatah MM, "Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 31, pp.418~424 (2019)
  5. Cho JH, "Long-term outcomes of endoscopic submucosal dissection for early gastric cancer : a comparison study to surgery using propensity score-matched analysis", Surg Endosc, 30, pp.3762~3773 (2016)
  6. Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer : systematic review and meta-analysis", Gut, 69, pp.2113~2121 (2020)
  7. Pimentel-Nunes P, "Management of epithelial precancerous conditions and lesions in the stomach(MAPS II) : European Society of Gastrointestinal Endoscopy(ESGE), European Helicobacter and Microbiota Study Group(EHMSG), European Society of Pathology(ESP), and Sociedade Portuguesa de Endoscopia Digestiva(SPED)guideline update 2019", Endoscopy, 51, pp.365~388 (2019)
  8. Song H, "Incidence of gastric cancer among patients with gastric precancerous lesions : observational cohort study in a low risk Western population", BMJ, 351, pp.h3867~ (2015)
  9. den Hoed CM, "Follow-up of premalignant lesions in patients at risk for progression to gastric cancer", Endoscopy, 45, pp.249~256 (2013)
  10. de Vries AC, "Gastric cancer risk in patients with premalignant gastric lesions : a nationwide cohort study in the Netherlands", Gastroenterology, 134, pp.945~952 (2008)
  11. "A Cochrane Risk Of Bias Assessment Tool: for Non-RandomizedStudies of Interventions (ACROBATNRSI), Version 1.0.0, 24 September 2014"[URL]
  12. Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 1, pp.87~97 (1969)
  13. Dixon MF, "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994", Am J Surg Pathol, 20, pp.1161~1181 (1996)
  14. Noh G, "Long-term follow up of serum pepsinogens in patients with gastric cancer or dysplasia after Helicobacter pylori eradication", J Gastroenterol Hepatol, 35, pp.1540~1548 (2020)
  15. Yoshida T, "Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer", Int J Cancer, 134, pp.1445~1457 (2014)
  16. Ohkusa T, "Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients", Aliment Pharmacol Ther, 20(Suppl 1), pp.25~32 (2004)
  17. Stewart LA, "Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement", JAMA, 313, pp.1657~1665 (2015)
  18. Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration", Ann Intern Med, 151, pp.W65~W94 (2009)
  19. Han JS, "A study of metachronous cancer after endoscopic resection of early gastric cancer", Scand J Gastroenterol, 46, pp.1099~1104 (2011)
  20. Seung Jun Han, "Long-Term Effects of Helicobacter pylori Eradication on Metachronous Gastric Cancer Development", Gut and Liver, 12(2), pp.133~141 (2018), 거트앤리버 소화기연관학회협의회
  21. Hanaoka N, "Autofluorescence imaging for predicting development of metachronous gastric cancer after Helicobacter pylori eradication", J Gastroenterol Hepatol, 25, pp.1844~1849 (2010)
  22. Iguchi M, "Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection", Int J Cancer, 139, pp.1150~1156 (2016)
  23. Moribata K, "Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication", Dig Endosc, 28, pp.434~442 (2016)
  24. Kato M, "Helicobacter pylori eradication prevents secondary gastric cancer in patients with mild-to-moderate atrophic gastritis", J Gastroenterol Hepatol, 36, pp.2083~2090 (2021)
  25. Kim SB, "Association between Helicobacter pylori status and metachronous gastric cancer after endoscopic resection", World J Gastroenterol, 22, pp.9794~9802 (2016)
  26. Maehata Y, "Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer", Gastrointest Endosc, 75, pp.39~46 (2012)
  27. Oura H, "Long-term use of proton pump inhibitors does not affect ectopic and metachronous recurrence of gastric cancer after endoscopic treatment", Scand J Gastroenterol, 55, pp.209~215 (2020)
  28. Rugge M, "Gastritis staging in clinical practice : the OLGA staging system", Gut, 56, pp.631~636 (2007)
  29. Rugge M, "OLGA gastritis staging for the prediction of gastric cancer risk : a long-term follow-up study of 7436 patients", Am J Gastroenterol, 113, pp.1621~1628 (2018)
  30. Kotelevets SM, "Updated Kimura-Takemoto classification of atrophic gastritis", World J Clin Cases, 9, pp.3014~3023 (2021)
  31. Kim EH, "The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis", Dig Liver Dis, 47, pp.663~668 (2015)
  32. 이선영, "Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection", The Korean Journal of Internal Medicine, 31(5), pp.835~844 (2016), 대한내과학회[DOI]
  33. Wang X, "The correlation between histological gastritis staging-‘OLGA", OLGIM’ and serum pepsinogen test in assessment of gastric atrophy, Scand J Gastroenterol, pp.2017, 52[DOI]
  34. 이주엽, "Correlations Among Endoscopic, Histologic and Serologic Diagnoses for the Assessment of Atrophic Gastritis", 대한암예방학회지, 19(1), pp.47~55 (2014), 대한암예방학회
  35. Jong Hyeon Jeong, "혈청 항벽세포 항체 양성 소견을 보인 자가면역성 위염 환자 5명에 대한 보고", Korean Journal of Helicobacter Upper Gastrointestinal Research, 21(3), pp.226~234 (2021), 대한상부위장관ㆍ헬리코박터학회[DOI]
  36. Shichijo S, "Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication", Gastrointest Endosc, 84, pp.618~624 (2016)
  37. Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
  38. Li WQ, "Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality : follow-up of a randomized intervention trial", BMJ, 366, pp.l5016~ (2019)
  39. Yan L, "Effect of Helicobacter pylori eradication on gastric cancer prevention : updated report from a randomized controlled trial with 26. 5 years of follow-up", Gastroenterology, 163, pp.154~162 (2022)

관련 논문AI추천

Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric CancerAmit Bhatt, Haruhisa Suzuki, Ichiro Oda, Masau Sekiguchi, Satoru Nonaka, Seiichiro Abe, Shigetaka Yoshinaga, Takeyoshi Minagawa, Yutaka Saito대한소화기내시경학회 · Clinical Endoscopy2018 · 제51권 제3호Risk Assessment of Metachronous Gastric Neoplasm after Endoscopic Resection for Early Gastric Cancer According to Age at Helicobacter pylori Eradication정현수, Cho Soo-Jeong, Kim Bokyung, Kim Jiyoon, Kim Sang Gyun, Lee Jun Hee, Lee Seunghan, Na Yun Suk, Oh Mi Jin거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호Long-Term Effects of Helicobacter pylori Eradication on Metachronous Gastric Cancer Development오수연, Hyun Chae Jung, Jae Yong Park, Ji Min Choi, Joo Hyun Lim, Joo Sung Kim, Jung Kim, Sang Gyun Kim, Seung Jun Han거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제2호Optimal Surveillance of Metachronous Gastric Lesion after Endoscopic Resection of Early Gastric CancerJoo Dong Chan, Kim Gwang Ha거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제5호Clinical Outcomes of Metachronous Gastric Cancer after Endoscopic Resection for Early Gastric CancerHyo-Joon Yang, Hyun Ju Kim, Hyunsoo Chung, Jae Yong Park, Jue Lie Kim, Jung Kim, Sang Gyun Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제2호Clinical outcomes of metachronous recurrence of gastric epithelial neoplasia based on Helicobacter pylori infection status and microsatellite stabilityJaeyoung Kim, Woo Chul Chung, Yeon-Ji Kim대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호

이 간행물의 다른 논문 (19건)

Could assessment of genetic susceptibility be an effective solution to prevent pancreatitis from occurring after endoscopic retrograde cholangiopancreatography?이재민pp. 783-784Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing전영우pp. 785-786Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerationsJuwhan Choi, Sung Yong Lee, Jae Kyeom Simpp. 787-796Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemiaSeung-Hwan Lee, 이정민pp. 797-809Long-acting interferon: pioneering disease modification of myeloproliferative neoplasmsSung-Yong Kim, Seug Yun Yoonpp. 810-817
원문 보기